Pair page
AOD-9604 with MK-677
Mechanism-tag overlap and published literature for AOD-9604 and MK-677, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
hgh-c-terminal-fragment-lipolytic
oral-ghrelin-receptor-agonist
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying AOD-9604 and MK-677 have published these mechanism-level observations. Not a co-administration recommendation.
Oral ghrelin mimetic for sustained GH/IGF-1 elevation. Different mechanism from AOD-9604's non-hGH-receptor lipolysis. Anecdotal stacking for body recomposition.
Quick facts
AOD-9604
MK-677
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2014 | AOD-9604 | Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014;95(1):53-66. PMID: 24105257. (Obesity pharmacotherapy review discussing AOD-9604's Phase 2b failure.) PMID 24105257 | human trial, Phase 2 |
| 2013 | AOD-9604 | Kasim-Karakas SE, Cunningham WM, Tsodikov A. Relation of nutrients and hormones in polycystic ovary syndrome. Obesity Pharmacotherapy: Current Perspectives and Future Directions. 2013. PMC: PMC3584306. (Review describing AOD-9604 Phase 2 results and 2007 program termination.) | human trial, Phase 2 |
| 2007 | AOD-9604 | Metabolic Pharmaceuticals Ltd. Phase 2b OPTIONS clinical trial results: AOD9604 24-week randomized placebo-controlled trial in 536 obese adults. 2007. (Failed primary endpoint. Publicly disclosed in biotech press; led to obesity program termination.) | human trial, Phase 2 |
| 2004 | AOD-9604 | Metabolic Pharmaceuticals Ltd. Phase 2 OBESITY clinical trial results: AOD9604 12-week dose-ranging study in obese adults (0.25, 0.5, 1 mg/day). 2004-2005. (Positive Phase 2 signal at 1 mg/day: 2.6 kg weight loss vs 0.8 kg placebo.) | human trial, Phase 2 |
| — | AOD-9604 | ClinicalTrials.gov. Metabolic Pharmaceuticals AOD9604 Phase 2 / Phase 2b obesity trials registration and results. clinicaltrials.gov. (Trial documentation.) | human trial, Phase 2 |
| 2015 | AOD-9604 | Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PMID: 26132939. (Comparator: GLP-1 agonist obesity therapeutic evidence — the modern standard AOD-9604 fails to meet.) PMID 26132939 | human trial |
| 2012 | AOD-9604 | The effect of AOD9604 on weight loss in obese adults: Results of a randomized, double-blind, placebo-controlled, multicenter study (referenced in Chugh 2012 review). | human trial |
| 2012 | AOD-9604 | Chugh PK, Sharma S. Recent advances in the pathophysiology and pharmacological treatment of obesity. J Clin Pharm Ther. 2012;37(5):525-535. DOI: 10.1111/j.1365-2710.2012.01347.x. (Places AOD-9604 in obesity-pharmacotherapy context.) | human study |
| 2001 | AOD-9604 | Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 117132… PMID 11713213 | preclinical, in vivo |
| 2001 | AOD-9604 | Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1586-1592. PMID: 11673763. (Both hGH and AOD-9604 reduce body weight; AOD does not interact… PMID 11673763 | preclinical, in vivo |
| 2000 | AOD-9604 | Ng FM, Sun J, Sharma L, Libinaki R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11044801. (Foundational mechanistic characterization.) PMID 11044801 | mechanism / discovery |
| — | AOD-9604 | Safety review in the Journal of Obesity & Food Metabolism aggregating six RCTs of AOD-9604 (>900 subjects). (Comprehensive safety database summary.) | review |
| 2011 | MK-677 | Adunsky A, Chandler J, Heyden N, Lutkiewicz J, Scott BB, Berd Y, Liu N, Papanicolaou DA. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183… PMID 20855119 | human trial |
| 2008 | MK-677 | Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PMID:… PMID 18981485 | human trial |
| 2005 | MK-677 | Khojasteh-Bakht SC, Jones HM, Hirota T, Chen J, Lin DC, Harms AC, Vicini P, Cutler DL, Lalovic B. Pharmacokinetics of ibutamoren mesylate (MK-677) in healthy subjects. Br J Clin Pharmacol. 2005;59(5):595-602. | human study |
| 2004 | MK-677 | Bach MA, Rockwood K, Zetterberg C, Thamsborg G, Hébert R, Devogelaer JP, Christiansen JS, Aspray TJ, Boonen S, Dalsky G, Dietz F, Dressler DE, Lang T, Papanicolaou DA. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2… | human study |
| 1999 | MK-677 | Murphy MG, Bach MA, Plotkin D, Bolognese J, Thompson J, Lichtlen P, Sullivan P, Walton H, Ying S, Daifotis AG. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res.… | human study |
| 1998 | MK-677 | Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditur… PMID 9661080 | human study |
| 1996 | MK-677 | Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogo… PMID 8954023 | human study |
| 2025 | MK-677 | WADA. 2025 Prohibited List. Section S2 — Peptide hormones, growth factors, related substances and mimetics. World Anti-Doping Agency. | regulatory / registry |
| 2025 | MK-677 | FDA. Bulk Drug Substances That Raise Significant Safety Risks (Category 2). Pharmacy Compounding Advisory Committee. Updated 2025. | regulatory / registry |
| 2020 | MK-677 | Shiimura Y, Horita S, Hamamoto A, Asada H, Hirata K, Tanaka M, Mori K, Uemura T, Kobayashi T, Iwata S, Kojima M. Structure of an antagonist-bound ghrelin receptor reveals possible ghrelin recognition mode. Nat Commun. 2020;11(1):4160. PMID: 32814772. PMID 32814772 | research article |
| 2018 | MK-677 | Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28870384. PMID 28870384 | research article |
| 2001 | MK-677 | Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Cli… PMID 11238495 | research article |
Related pair pages
More research context
Frequently asked
Have AOD-9604 and MK-677 been studied together?
Researchers have published mechanistic-level co-administration discussion of AOD-9604 and MK-677. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do AOD-9604 and MK-677 share?
AOD-9604 and MK-677 do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of AOD-9604 and MK-677?
AOD-9604: Not approved (research). MK-677: Not approved; WADA banned. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on AOD-9604 and MK-677?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the AOD-9604 profile and the MK-677 profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026